SEED Therapeutics

SEED Therapeutics is developing novel "molecular glue" modalities using its unique RITE3 targeted protein degradation (TPD) platform, designed to target 80% of disease-driving proteins previously considered undruggable in cancer, neurodegenerative disease, and more.